Advanced Biomed Inc(ADVB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | 51.44 | EPS (ttm) | 0.16 | Insider Own | 55.36% | Shs Outstand | 1.4M | Perf Week | -12.87% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.7M | Perf Month | 7.76% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 0.08% | Short Float | 2.21% | Perf Quarter | 104.24% |
| Income | 0.00B | P/S | - | EPS this Y | - | Inst Trans | -0.01% | Short Ratio | 0.01 | Perf Half Y | 52.8% |
| Sales | 0.00B | P/B | 39.29 | EPS next 5Y | - | ROA | 59.9% | Short Interest | 0.02M | Perf YTD | 40.34% |
| Book/sh | 0.21 | P/C | 169.12 | EPS past 3/5Y | 10.67% -12.01% | ROE | 84.61% | 52W High | -66.2% ($24.23) | Perf Year | -16.02% |
| Cash/sh | 0.05 | P/FCF | - | Sales past 3/5Y | - | ROIC | 58.89% | 52W Low | 126.87% ($3.61) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 271.18% | Gross Margin | - | Volatility(W/M) | 8.01% 12.99% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.38 | EPS Q/Q | 69.15% | Profit Margin | - | RSI (14) | 45.82 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.38 | Sales Q/Q | - | SMA20 | -8.6% ($8.96) | Beta | -0.27 | Target Price | - |
| Payout | - | Debt/Eq | 0.07 | Earnings | - | SMA50 | -3.18% ($8.46) | Rel Volume | 0.05 | Prev Close | $8.85 |
| Employees | 31 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 30.69% ($6.27) | Avg Volume(3M) | 1.77M | Price | $8.19 |
| IPO | 2025/3/6 | Option/Short | No/Yes | Trades | 1194 | Volume | 92,196 | Change | -7.46% |
Company
ADVB is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🔬 is a microcap biotech company specializing in precision medicine diagnostics and research, headquartered in Tainan, Taiwan. Leveraging semiconductor microfluidic chip technology, the company detects and analyzes circulating tumor cells (CTCs) in the blood and develops precision medicine solutions, including its 3D cell culture platform A+PerfusC, which predicts responsiveness to anticancer treatment.
Over the past 1 year, on the lower side
66% below its 1-year high.
ADVB makes money exceptionally well
Tap to view numbers
The price looks about right
Trading at 51.4 times earnings.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 0.1%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $14M.
ADVB $14M PER 51.4
TMO $225B PER 32.8
DHR $141B PER 35.5
NTRA $47B PER -
FAQ
What kind of company is ADVB?
ADVB belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of ADVB?
The market cap of ADVB is approximately $14M, ranking 5,424 within its sector.
What is the P/E ratio of ADVB?
ADVB has a P/E ratio of approximately 51.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ADVB?
ADVB has recorded a 52-week high of $24.23 and a low of $3.61.
